Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ILMN stock price vs CL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CL's multiple
Needs CL P/E.
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
COLGATE-PALMOLIVE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
ILMN vs TMO
AGILENT TECHNOLOGIES, INC.
ILMN vs A
DANAHER CORP /DE/
ILMN vs DHR
BIO-RAD LABORATORIES, INC.
ILMN vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
ILMN vs PACB
Natera, Inc.
ILMN vs NTRA
PROCTER & GAMBLE Co
ILMN vs PG
JOHNSON & JOHNSON
ILMN vs JNJ
CHURCH & DWIGHT CO INC /DE/
ILMN vs CHD
KIMBERLY CLARK CORP
ILMN vs KMB
EDGEWELL PERSONAL CARE Co
ILMN vs EPC
UNILEVER PLC
ILMN vs UL
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ILMN can sustain its superior margins despite negative revenue growth, then hold or accumulate selectively because the stock is not expensive on P/E and the balance sheet is much cleaner than CL’s, even though near-term upside appears limited.
On P/E, ILMN trades at 34.6x versus CL at 36.2x, so the stock is not expensive relative to this CL despite a higher current price. The valuation picture is mixed because the implied price only suggests 4.5% upside, while the DCF range is far below the current price, indicating sensitivity to assumptions.
Supporting Metrics
